Krista Fager

476 total citations
11 papers, 374 citations indexed

About

Krista Fager is a scholar working on Genetics, Hematology and Oncology. According to data from OpenAlex, Krista Fager has authored 11 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 6 papers in Hematology and 5 papers in Oncology. Recurrent topics in Krista Fager's work include Chronic Lymphocytic Leukemia Research (6 papers), Chronic Myeloid Leukemia Treatments (6 papers) and HER2/EGFR in Cancer Research (4 papers). Krista Fager is often cited by papers focused on Chronic Lymphocytic Leukemia Research (6 papers), Chronic Myeloid Leukemia Treatments (6 papers) and HER2/EGFR in Cancer Research (4 papers). Krista Fager collaborates with scholars based in United States and Germany. Krista Fager's co-authors include Kelly McGlinchey, Amy Camuso, Ivan Inigo, David Kan, Christine Flefleh, Stephen Castaneda, Feng Luo, Robert A. Kramer, Zheng Yang and Francis Y. Lee and has published in prestigious journals such as Blood, Cancer Research and Clinical Cancer Research.

In The Last Decade

Krista Fager

11 papers receiving 366 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Krista Fager United States	8	161	135	114	113	84	11	374
Amy Camuso United States	9	162 1.0×	163 1.2×	114 1.0×	113 1.0×	84 1.0×	12	402
Mei-Li Wen United States	9	166 1.0×	120 0.9×	109 1.0×	94 0.8×	84 1.0×	17	333
Jeffrey Keats United States	8	165 1.0×	156 1.2×	118 1.0×	185 1.6×	92 1.1×	12	402
Kees Bol Netherlands	7	225 1.4×	283 2.1×	89 0.8×	259 2.3×	25 0.3×	10	537
Roberta Rostagno Italy	5	284 1.8×	93 0.7×	227 2.0×	121 1.1×	142 1.7×	6	464
Josephine L. Klitgaard United States	7	108 0.7×	133 1.0×	171 1.5×	178 1.6×	31 0.4×	11	426
Pekka Anttila Finland	12	261 1.6×	129 1.0×	132 1.2×	244 2.2×	36 0.4×	31	404
Daisy Moreno United States	7	201 1.2×	61 0.5×	174 1.5×	178 1.6×	54 0.6×	9	430
Matthew S. Zabriskie United States	9	416 2.6×	170 1.3×	301 2.6×	307 2.7×	113 1.3×	24	720
Koshi Akahane Japan	14	181 1.1×	217 1.6×	94 0.8×	301 2.7×	24 0.3×	63	658

Countries citing papers authored by Krista Fager

Since Specialization

Citations

This map shows the geographic impact of Krista Fager's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Krista Fager with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Krista Fager more than expected).

Fields of papers citing papers by Krista Fager

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Krista Fager. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Krista Fager. The network helps show where Krista Fager may publish in the future.

Co-authorship network of co-authors of Krista Fager

This figure shows the co-authorship network connecting the top 25 collaborators of Krista Fager. A scholar is included among the top collaborators of Krista Fager based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Krista Fager. Krista Fager is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Luo, Feng, Yu Chen Barrett, Zheng Yang, et al.. (2008). Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor. Cancer Chemotherapy and Pharmacology. 62(6). 1065–1074. 43 indexed citations

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2006). Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure. Clinical Cancer Research. 12(23). 7180–7186. 113 indexed citations

Wild, Robert A., Krista Fager, Christine Flefleh, et al.. (2006). Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Molecular Cancer Therapeutics. 5(1). 104–113. 60 indexed citations

Lee, Francis Y., Louis J. Lombardo, Amy Camuso, et al.. (2005). BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Cancer Research. 65. 159–159. 38 indexed citations

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2005). Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft. Cancer Chemotherapy and Pharmacology. 56(5). 455–464. 66 indexed citations

Lee, Francis Y., Mei-Li Wen, Rajeev S. Bhide, et al.. (2005). Dasatinib (BMS-354825) Overcomes Multiple Mechanisms of Imatinib Resistance in Chronic Myeloid Leukemia (CML).. Blood. 106(11). 1994–1994. 14 indexed citations

Lee, Francis Y., Mei-Li Wen, Amy Camuso, et al.. (2005). Quiescent Chronic Myelogenous Leukemia (CML) Cells Are Resistant to BCR-ABL Inhibitors but Preferentially Sensitive to BMS-214662, a Farnesyltransferase Inhibitor (FTI) with Unique Quiescent-Cell Selective Cytotoxicity.. Blood. 106(11). 1993–1993. 5 indexed citations

Luo, Feng, Zheng Yang, Huijin Dong, et al.. (2005). Prediction of Active Drug Plasma Concentrations Achieved in Cancer Patients by Pharmacodynamic Biomarkers Identified from the Geo Human Colon Carcinoma Xenograft Model. Clinical Cancer Research. 11(15). 5558–5565. 22 indexed citations

Lee, Francis Y., Louis J. Lombardo, R. M. Borzilleri, et al.. (2004). Pharmacodynamic analysis of target inhibition and tumor endothelial cell death in biopsies obtained from patients treated with the VEGF receptor antagonists SU5416 or SU6668. Cancer Research. 64. 921–921. 3 indexed citations

10.

Luo, Feng, Zheng Yang, Amy Camuso, et al.. (2004). Pharmacokinetics- and Pharmacodynamics-Guided Optimization of the Dose and Treatment Schedule for the Dual SRC/ABL Inhibitor BMS-354825.. Blood. 104(11). 1987–1987. 1 indexed citations

11.

Wild, Robert A., Stephen Castaneda, Christine Flefleh, et al.. (2004). BMS-354825, a Dual SRC/ABL Kinase Inhibitor, Displays Potent Anti-Tumor Activity in a Model of Intracranial CML Growth.. Blood. 104(11). 1988–1988. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact